Pancreatic cancer patients with a high expression of MAPT, EPB41L3, LOC100128977, and LOC100130148 had an evidently higher overall survival as compared with those with a low expression of MAPT (p = 0.0034), EPB41L3 (p = 0.0088), LOC100128977 (p = 0.0077), and LOC100130148 (p = 0.0017). This evidence concerns the gene MAPT and pancreatic neoplasm.